Literature DB >> 7531709

Activation of interferon-inducible 2'-5' oligoadenylate synthetase by adenoviral VAI RNA.

S Y Desai1, R C Patel, G C Sen, P Malhotra, G D Ghadge, B Thimmapaya.   

Abstract

2'-5' oligoadenylate (2-5(A)) synthetase and protein kinase, RNA activated (PKR) are the only two known enzymes that bind double-stranded RNA (dsRNA) and get activated by it. We have previously identified their dsRNA binding domains, which do not have any sequence homology. Here, we report a profound difference between the two enzymes with respect to the structural features of the dsRNA that are required for their activation. The adenoviral virus-associated type I (VAI) RNA cannot activate PKR, although it binds to the protein and thereby prevents its activation by authentic dsRNA. In contrast, we observed that VAI RNA can both bind and activate 2-5(A) synthetase. Mutations in VAI RNA, which removed occasional mismatches present in its double-stranded stems, markedly enhanced its 2-5(A) synthetase-activating capacity. These mutants, however, are incapable of activating PKR. Other mutations, which disrupted the structure of the central stem-loop region of the VAI RNA, reduced its ability to activate 2-5(A) synthetase. These debilitated mutants could bind to the synthetase protein, although they fail to bind to PKR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531709     DOI: 10.1074/jbc.270.7.3454

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

2.  Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Authors:  Zeng B Zhu; Angel A Rivera; Sharmila K Makhija; Baogen Lu; Minghui Wang; Miiru Izumi; Robert J Cerfolio; Mariam A Stoff-Khalili; Fen Zhou; Koichi Takayama; Gene P Siegal; David T Curiel
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

3.  The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo.

Authors:  R C Patel; P Stanton; N M McMillan; B R Williams; G C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

4.  Dissection of the adenoviral VA RNAI central domain structure reveals minimum requirements for RNA-mediated inhibition of PKR.

Authors:  Jo L Wilson; Virginia K Vachon; S Sunita; Samantha L Schwartz; Graeme L Conn
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

5.  The Flvr-encoded murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells.

Authors:  H Elbahesh; B K Jha; R H Silverman; S V Scherbik; M A Brinton
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

6.  Domain interactions in adenovirus VAI RNA mediate high-affinity PKR binding.

Authors:  Katherine Launer-Felty; James L Cole
Journal:  J Mol Biol       Date:  2014-01-04       Impact factor: 5.469

Review 7.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

8.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Authors:  Jian-Qiu Han; David J Barton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

Review 9.  Sequence-non-specific effects of RNA interference triggers and microRNA regulators.

Authors:  Marta Olejniczak; Paulina Galka; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2009-10-20       Impact factor: 16.971

Review 10.  Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes.

Authors:  M Kumar; G G Carmichael
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.